Invasive Meningococcal disease in Uruguay
Epidemiology and directives. May 2002
Keywords:
MENINGOCOCCAL MENINGITIS, NEISSERIA MENINGITIDIS, URUGUAY
Abstract
In recent times epidemiology of invasive meningococcal disease (EIM) in Uruguay has been changing: serogroup C cases have decreased whereas serogroup B increased.
Last year, Neisseria meningitidis group B epidemic was suspected since cases increased, age of patients moved to range older than 5 years, an epidemic peak appeared in a small city, deaths of patients older than 5 years, and predominance of one strain (B:4,7:P1.15,19) over a combi-nation of Neisseria meningitidis group B strains.
Epidemiologic and microbiologic data supporting countrywide immunization with antimeningococcal B-C vaccine (Finlay Institute) in 4 to 19 year-old-people are shown.
References
1) Diaermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, et al. Epidemic Serogroup B Meningococcal Disease in Oregon. The evolving epidemiology of the ET – 5 strain. JAMA 1999; 281: 1493-7.
2) Cartwright KA, Stuart JM, Noah ND. An outbreak of meningococcal disease in Goucestersheire. Lancet 1986; 2(6): 558-61.
3) Peltola H. Prophylaxis of bacterial meningitis. Bacterial menintitis. Infect Dis Clin North Am 1999; 13(3): 685-710, viii.
4) Lepow ML, Perkins BA, Hughes PA, Poolman JT. Meningococcal Vaccines. In: Plotkin SA, Oreintein WA. Vaccines, 3rd ed. Philadelphia: Saunders, 1999.
5) Wenger JD. Serogroup B meningococcal disease: new outbreaks, new strategies. JAMA 1999; 281 8(16): 1541-3.
6) Instituto de Pediatría. Clínicas Pediátricas A, B, C, Servicio de Emergencia. Meningoencefalitis aguda supurada. In: Pautas de diagnóstico, tratamiento y prevención. Atención Pediátrica. 5nd ed. Montevideo: Oficina del Libro AEM, 2000: 131-8.
7) American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, ed. 2000 Red Book, Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village: American Academy of Pediatrics, 2000: 396-401.
8) Asociación Americana de Infectología. Asociación Española de Pediatría. Sociedad Latinoamericana de Pediatría. Vacunación contra el meningococo. In: Manual de Vacunas en Pediatría. 2nd ed. Latinoamericana, 2000: 165-78.
9) de Moraes JC, Perkins Ba, Camargo MCC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective efficacy of a serogroup B meningococcal vaccine in São Paulo, Brazil. Lancet 1992; 340:1074-8.
10) Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case control study. Int J Epidemiol 1995; 24: 1050-7.
11) Costa EA, Martins H, Klein CH. Avaliacão da protecão conferida pela vacina antimeningócica BC no Estado de Santa Catarina, Brasil, 1990-1992. Rev Saude Pública 1999; 30: 460-70.
12) Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Hoiby EA, et al. Inmunogenicity of two efficacious outer membrane protein-based serogoup B meningococcal vaccines among adults in Iceland. J Infect Dis 1998; 177: 683-91.
13) Tappero JW, Lagos R, Ballesteros A, Plikaytis B, Williams D, Dukes J, et al. Inmunogenicity of 2 Serogroup B outer membrana protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281: 1520-7.
14) Sierra GV, Campa HC, Varcacel NM, García IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meinigitidis: Protection trial and mass vaccination. Results in Cuba. NIPH Ann 1991; 14: 195-207. (Discussion 208-10).
15) Peter G. Update on meningococcal vaccine. Pediatr Infect Dis J 2001; 20(3): 311-2.
16) Pollard AJ, Galassini R, Rouppe van der Voort EM, Hibberd M, Booy R, Langford P, et al. Cellular Immune Responses to Neisseria meningitides in Children. Infect Immun 1999; 67(5): 2452-63.
17) Pollard AJ, Galassini R, Rouppe van der Voort EM, Booy R, Langford P, Nadel S, et al. Humoral Immune Responses to Neisseria meningitidis in Children. Infection and Immunity; 1999; 67(5): 2441-51.
2) Cartwright KA, Stuart JM, Noah ND. An outbreak of meningococcal disease in Goucestersheire. Lancet 1986; 2(6): 558-61.
3) Peltola H. Prophylaxis of bacterial meningitis. Bacterial menintitis. Infect Dis Clin North Am 1999; 13(3): 685-710, viii.
4) Lepow ML, Perkins BA, Hughes PA, Poolman JT. Meningococcal Vaccines. In: Plotkin SA, Oreintein WA. Vaccines, 3rd ed. Philadelphia: Saunders, 1999.
5) Wenger JD. Serogroup B meningococcal disease: new outbreaks, new strategies. JAMA 1999; 281 8(16): 1541-3.
6) Instituto de Pediatría. Clínicas Pediátricas A, B, C, Servicio de Emergencia. Meningoencefalitis aguda supurada. In: Pautas de diagnóstico, tratamiento y prevención. Atención Pediátrica. 5nd ed. Montevideo: Oficina del Libro AEM, 2000: 131-8.
7) American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, ed. 2000 Red Book, Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village: American Academy of Pediatrics, 2000: 396-401.
8) Asociación Americana de Infectología. Asociación Española de Pediatría. Sociedad Latinoamericana de Pediatría. Vacunación contra el meningococo. In: Manual de Vacunas en Pediatría. 2nd ed. Latinoamericana, 2000: 165-78.
9) de Moraes JC, Perkins Ba, Camargo MCC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective efficacy of a serogroup B meningococcal vaccine in São Paulo, Brazil. Lancet 1992; 340:1074-8.
10) Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case control study. Int J Epidemiol 1995; 24: 1050-7.
11) Costa EA, Martins H, Klein CH. Avaliacão da protecão conferida pela vacina antimeningócica BC no Estado de Santa Catarina, Brasil, 1990-1992. Rev Saude Pública 1999; 30: 460-70.
12) Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Hoiby EA, et al. Inmunogenicity of two efficacious outer membrane protein-based serogoup B meningococcal vaccines among adults in Iceland. J Infect Dis 1998; 177: 683-91.
13) Tappero JW, Lagos R, Ballesteros A, Plikaytis B, Williams D, Dukes J, et al. Inmunogenicity of 2 Serogroup B outer membrana protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281: 1520-7.
14) Sierra GV, Campa HC, Varcacel NM, García IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meinigitidis: Protection trial and mass vaccination. Results in Cuba. NIPH Ann 1991; 14: 195-207. (Discussion 208-10).
15) Peter G. Update on meningococcal vaccine. Pediatr Infect Dis J 2001; 20(3): 311-2.
16) Pollard AJ, Galassini R, Rouppe van der Voort EM, Hibberd M, Booy R, Langford P, et al. Cellular Immune Responses to Neisseria meningitides in Children. Infect Immun 1999; 67(5): 2452-63.
17) Pollard AJ, Galassini R, Rouppe van der Voort EM, Booy R, Langford P, Nadel S, et al. Humoral Immune Responses to Neisseria meningitidis in Children. Infection and Immunity; 1999; 67(5): 2441-51.
Published
2002-05-31
How to Cite
1.
Pírez M C, Picón T, Galazka J, Quian J, Gutiérrez S, Ferrari AM, Montano A, Rubio I. Invasive Meningococcal disease in Uruguay. Rev. Méd. Urug. [Internet]. 2002May31 [cited 2024Nov.17];18(1):83-8. Available from: http://www2.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/1005
Section
Reports
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
